Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bedica
- Development stage
- Unknown
- Lead developer
- Bedrocan International
- Modality
- Small Molecules
- Administration
- Inhalation, Oral
01
Overview
Bedica is a standardized, pharmaceutical-grade cannabis chemovar (Cannabis sativa L. 'Talea') developed by Bedrocan International. Classified as an indica-type cannabis flower, it is produced under EU GMP-certified conditions to ensure a consistent chemical profile across batches. The product contains approximately 14% delta-9-tetrahydrocannabinol (THC) and less than 1% cannabidiol (CBD). Its terpene profile is characterized by high levels of myrcene, which is associated with sedating and calming effects. Bedica serves as a plant-derived active pharmaceutical ingredient (API) and botanical raw material for medicinal cannabis programs, clinical research, and the development of pharmaceutical formulations. It is supplied in various forms, including whole dried flowers (flos) and granulated versions, to patients and researchers in multiple countries including the Netherlands, Germany, Finland, Israel, Italy, Macedonia, and Poland.
- Brand names
- Bedica
- Other names
- Cannabis sativa L. TaleaBedica flos
02
Targets
CNR1 (Cannabinoid receptor 1)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))
Beyond the preview
Go deeper on Bedica.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bedica.